Health Care Cost

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported.

Lawmakers grilled Martin Makary, MD, MPH, on transparency, his plans for mifepristone and his stance on the recently cancelled Vaccine Advisory Committee meeting during Thursday’s senate hearing to be the next FDA commissioner.

The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for women with type 1 diabetes, according to a brief report published in Diabetes Technology & Therapeutics.

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications consumed more than 80% of Medicare Part D spending, researchers reported.

Billing patients for their messages in a patient portal led to a moderate reduction in questions for one large integrated health care provider but was generally accepted by clinicians, according to the results of recent research

Individuals with spondyloarthritis can reduce their number of rheumatology visits through patient-initiated follow-up with asynchronous telehealth, without sacrificing outcomes, according to data published in The Lancet Rheumatology.

A real-world study of patients with overweight or obesity and heart failure demonstrated that initiation of semaglutide 2.4 mg corresponded with a mean total medical cost reduction of $6,512 during a 1-year follow-up period.

SAN ANTONIO — Semaglutide 2.4 mg was associated with reduced year-over-year health care costs, up to $6,500, among patients with overweight or obesity and heart failure, a speaker reported.

Women who traveled out of state for abortion care were more likely to incur catastrophic health expenditures, which were associated with increased symptoms of anxiety and depression, survey data show.

The Federal Trade Commission announced it has filed an administrative complaint against three pharmacy benefit managers alleging “anticompetitive and unfair” rebate practices that have artificially inflated the price of insulin drugs.